Citi keeps Sell rating on Moderna after melanoma trial data, PT $80

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. DOX
4. AMGN
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Citi keeps Sell rating on Moderna after melanoma trial data, PT $80

Citi reiterates sell rating on Moderna with $80 price target

October 26, 2026 6:38 AM EDT

Citi analyst Geoff Meacham reiterated a Sell rating and $80.00 price target on Moderna (NASDAQ: MRNA).

Meacham said Moderna's ESMO investor call focused on the potential of intismeran, with management and participating key opinion leaders emphasizing its neoantigen-specific immune response, efficacy across melanoma risk... More

Citi reiterates Sell rating on Moderna with $80 price target

October 23, 2026 9:48 AM EDT

Citi analyst Geoff Meacham reiterated a Sell rating and $80.00 price target on Moderna (NASDAQ: MRNA).

Meacham outlined ten reasons why positive melanoma trial data from the INTerpath-001 study do not address his concerns about the company's valuation. He noted that one successful study in... More